Experimental therapy in myelofibrosis with myeloid metaplasia
暂无分享,去创建一个
[1] D. Rondelli. Allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2008, Haematologica.
[2] W. Vainchenker,et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.
[3] H. Kantarjian,et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. , 2006, Blood.
[4] Sandra A. Moore,et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.
[5] R. Levine,et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.
[6] R. Mesa,et al. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis , 2006, Cancer.
[7] R. Schiffelers,et al. ICS-283: a system for targeted intravenous delivery of siRNA , 2006, Expert opinion on drug delivery.
[8] N. Donato,et al. The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway , 2006 .
[9] N. Donato,et al. Degradation of c-Myc by WP1130 Through Activation of a Novel Proteasomal-Dependent Pathway , 2006 .
[10] R. Mesa,et al. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2V617F and response to erythropoietin therapy , 2006, Cancer.
[11] L. Bañez,et al. VEGF inhibitors in cancer therapy. , 2006, Current pharmaceutical design.
[12] A. Kelso,et al. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells. , 2006, Cancer research.
[13] G. Barosi,et al. Glivec/STI571 Treatment Stimulates Megakaryopoiesis and Normalizes PDGF Receptor beta Kinase Expression in Thrombocytopenic Patients with Myeloid Metaplasia with Myelofibrosis. , 2005 .
[14] W. Vainchenker,et al. Proteasome Inhibitor Bortezomib Can Inhibit Bone Marrow Fibrosis Development in a Murine Model of Myelofibrosis. , 2005 .
[15] B. Cheson,et al. A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL). , 2005 .
[16] D. Steensma,et al. The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .
[17] A. Tefferi,et al. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia , 2005, Cancer.
[18] J. Reilly,et al. Der(6)t(1;6)(q21–23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia , 2005, British journal of haematology.
[19] Qingshan Li,et al. Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.
[20] J. Issa,et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Hoffman,et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. , 2005, Blood.
[22] H. Koeffler,et al. Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. , 2005, Leukemia research.
[23] A. Pancrazzi,et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. , 2005, Blood.
[24] Stefan N. Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.
[25] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[26] W. Vainchenker,et al. Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. , 2005, Cancer research.
[27] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[28] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[29] Randy Allred,et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.
[30] A. Dalgleish,et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. , 2005, Microvascular research.
[31] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[32] Jonathan M. Yingling,et al. Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.
[33] R. Mesa,et al. A Phase 2 Consortium (P2C) Trial of R115777 (Tipifarnib) in Myelofibrosis with Myeloid Metaplasia. , 2004 .
[34] M. Weller,et al. SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo , 2004, Cancer Research.
[35] J. S. Sawyer. Synthesis and Activity of New Aryl‐ and Heteroaryl‐Substituted 5,6‐Dihydro‐4H‐pyrrolo[1,2‐b]pyrazole Inhibitors of the Transforming Growth Factor‐β Type I Receptor Kinase Domain. , 2004 .
[36] J. Dupont,et al. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. , 2004, Clinical colorectal cancer.
[37] The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] A. Dalgleish,et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Françoise Gellibert,et al. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. , 2004, Journal of medicinal chemistry.
[40] R. Mesa,et al. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. , 2004, Mayo Clinic proceedings.
[41] M. Griesshammer,et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. , 2004, Blood.
[42] David Bebbington,et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.
[43] W. Vainchenker,et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. , 2004, Experimental hematology.
[44] E. Ralfkiær,et al. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis , 2003, American journal of hematology.
[45] H. Hasselbalch. SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis. , 2003, Medical hypotheses.
[46] Z. Estrov,et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. , 2003, Blood.
[47] G. Wolbring,et al. Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs , 2003, Journal of Pharmacology and Experimental Therapeutics.
[48] H. Kantarjian,et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disorders , 2003, Cancer.
[49] M. Heinrich,et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.
[50] M. Martyré. Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. , 2003, Current hematology reports.
[51] H. Kantarjian,et al. Phase II study of SU5416—a small‐molecule, vascular endothelial growth factor tyrosine‐kinase receptor inhibitor—in patients with refractory myeloproliferative diseases , 2003, Cancer.
[52] A. Tefferi,et al. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. , 2003, Blood.
[53] R. Kurzrock,et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. , 2003, Blood.
[54] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] W. Vainchenker,et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. , 2002, Blood.
[56] A. Migliaccio,et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). , 2002, Blood.
[57] D. Steensma,et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. , 2002, Blood.
[58] Jen-Chin Wang,et al. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation , 2002, British journal of haematology.
[59] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[60] Ruth Lehr,et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). , 2002, Journal of medicinal chemistry.
[61] O. Haas,et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. , 2002, Blood.
[62] W. Vainchenker,et al. Prominent role of TGF-1 in thrombopoietin-induced myelofibrosis in mice , 2002 .
[63] S. Margolin,et al. A phase II trial of pirfenidone (5‐methyl‐1‐phenyl‐2‐[1H]‐pyridone), a novel anti‐fibrosing agent, in myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.
[64] R. Mesa,et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.
[65] N. Kinukawa,et al. Primary Chronic Myelofibrosis: Clinical and Prognostic Evaluation in 336 Japanese Patients , 2001, International journal of hematology.
[66] W. R. Bishop,et al. Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules* , 2000, The Journal of Biological Chemistry.
[67] F. Wendling,et al. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. , 2000, Blood.
[68] P. Rameshwar,et al. NF-κB as a Central Mediator in the Induction of TGF-β in Monocytes from Patients with Idiopathic Myelofibrosis: An Inflammatory Response Beyond the Realm of Homeostasis1 , 2000, The Journal of Immunology.
[69] A. Tefferi. Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.
[70] J. Mestan,et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.
[71] Gilla Kaplan,et al. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production , 1999 .
[72] R. Kurzrock,et al. RAS and leukemia: from basic mechanisms to gene-directed therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] G. Prendergast,et al. Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.
[74] J. Herman,et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.
[75] W. Vainchenker,et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. , 1997, Blood.
[76] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[77] J. Esteve,et al. Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosis , 1997, British journal of haematology.
[78] P. Morel,et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.
[79] A. Levitzki,et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.
[80] J. Reilly,et al. Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis , 1994, British journal of haematology.
[81] Arturo Pereira,et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. , 1991, Acta haematologica.
[82] P. Fialkow,et al. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. , 1978, Blood.